help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sgambato, A.
Right arrow Articles by Cittadini, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sgambato, A.
Right arrow Articles by Cittadini, A.
(American Journal of Pathology. 2003;162:849-860.)
© 2003 American Society for Investigative Pathology

Dystroglycan Expression Is Frequently Reduced in Human Breast and Colon Cancers and Is Associated with Tumor Progression

Alessandro Sgambato*, Mario Migaldi{dagger}, Micaela Montanari*, Andrea Camerini*, Andrea Brancaccio{ddagger}, Giulio Rossi{dagger}, Rodolfo Cangiano*, Carmen Losasso{ddagger}, Giovanni Capelli§, Gian Paolo Trentini{dagger} and Achille Cittadini*

From the Centro di Ricerche Oncologiche "Giovanni XXIII," Istituto di Patologia Generale,* the Istituto di Chimica del Riconoscimento Molecolare,{ddagger} Sezione di Roma (Consiglio Nazionale Ricerche) c/o Istituto di Biochimica e Biochimica Clinica, and the Istituto di Igiene,§ Catholic University, Rome; and the Dipartimento Misto di Anatomia Patologica e di Medicina Legale,{dagger} Sezione di Anatomia Patologica, University of Modena and Reggio Emilia, Modena, Italy

Dystroglycan (DG) is an adhesion molecule responsible for crucial interactions between extracellular matrix and cytoplasmic compartment. It is formed by two subunits, {alpha}-DG (extracellular) and ß-DG (transmembrane), that bind to laminin in the matrix and dystrophin in the cytoskeleton, respectively. In this study we evaluated by Western blot analysis the expression of DG in a series of human cancer cell lines of various histogenetic origin and in a series of human primary colon and breast cancers. Decreased expression of DG was observed in most of the cell lines and in both types of tumors and correlated with higher tumor grade and stage. Analysis of the mRNA levels suggested that expression of DG protein is likely regulated at a posttranscriptional level. Evaluation of {alpha}-DG expression by immunostaining in a series of archival cases of primary breast carcinomas confirmed that {alpha}-DG expression is lost in a significant fraction of tumors (66%). Loss of DG staining correlated with higher tumor stage (P = 0.022), positivity for p53 (P = 0.033), and high proliferation index (P = 0.045). A significant correlation was also observed between loss of {alpha}-DG and overall survival (P = 0.013 by log-rank test) in an univariate analysis. These data indicate that DG expression is frequently lost in human malignancies and suggest that this glycoprotein might play an important role in human tumor development and progression.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
K. Fernandez, Y. Serinagaoglu, S. Hammond, L. T. Martin, and P. T. Martin
Mice Lacking Dystrophin or {alpha} Sarcoglycan Spontaneously Develop Embryonal Rhabdomyosarcoma with Cancer-Associated p53 Mutations and Alternatively Spliced or Mutant Mdm2 Transcripts
Am. J. Pathol., January 1, 2010; 176(1): 416 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
A. Rettino, F. Rafanelli, G. Genovese, M. Goracci, R. A. Cifarelli, A. Cittadini, and A. Sgambato
Identification of Sp1 and GC-boxes as transcriptional regulators of mouse Dag1 gene promoter
Am J Physiol Cell Physiol, November 1, 2009; 297(5): C1113 - C1123.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. B.-V. de Bernabe, K.-i. Inamori, T. Yoshida-Moriguchi, C. J. Weydert, H. A. Harper, T. Willer, M. D. Henry, and K. P. Campbell
Loss of {alpha}-Dystroglycan Laminin Binding in Epithelium-derived Cancers Is Caused by Silencing of LARGE
J. Biol. Chem., April 24, 2009; 284(17): 11279 - 11284.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
Y. Gong, R. Zhang, J. Zhang, L. Xu, F. Zhang, W. Xu, Y. Wang, Y. Chu, and S. Xiong
{alpha}-Dystroglycan is involved in positive selection of thymocytes by participating in immunological synapse formation
FASEB J, May 1, 2008; 22(5): 1426 - 1439.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
M. L. Weir, M. L. Oppizzi, M. D. Henry, A. Onishi, K. P. Campbell, M. J. Bissell, and J. L. Muschler
Dystroglycan loss disrupts polarity and {beta}-casein induction in mammary epithelial cells by perturbing laminin anchoring
J. Cell Sci., October 1, 2006; 119(19): 4047 - 4058.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
M. Schneider, A. A. Khalil, J. Poulton, C. Castillejo-Lopez, D. Egger-Adam, A. Wodarz, W.-M. Deng, and S. Baumgartner
Perlecan and Dystroglycan act at the basal side of the Drosophila follicular epithelium to maintain epithelial organization
Development, October 1, 2006; 133(19): 3805 - 3815.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
R. Barresi and K. P. Campbell
Dystroglycan: from biosynthesis to pathogenesis of human disease
J. Cell Sci., January 15, 2006; 119(2): 199 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Singh, Y. Itahana, S. Knight-Krajewski, M. Kanagawa, K. P. Campbell, M. J. Bissell, and J. Muschler
Proteolytic Enzymes and Altered Glycosylation Modulate Dystroglycan Function in Carcinoma Cells
Cancer Res., September 1, 2004; 64(17): 6152 - 6159.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society for Investigative Pathology.